Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Rallybio Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RLYB
Nasdaq
8731
https://rallybio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Rallybio Corp
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
- Apr 17th, 2024 8:01 pm
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
- Apr 12th, 2024 2:23 pm
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
- Apr 10th, 2024 8:01 pm
J&J, Rallybio partner on drug development for rare fetal condition
- Apr 10th, 2024 5:01 pm
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
- Apr 1st, 2024 2:05 pm
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 12th, 2024 12:00 pm
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
- Feb 26th, 2024 1:00 pm
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
- Feb 6th, 2024 1:00 pm
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?
- Jan 29th, 2024 3:11 pm
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
- Jan 4th, 2024 1:00 pm
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
- Dec 20th, 2023 1:00 pm
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
- Dec 9th, 2023 5:00 pm
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
- Nov 28th, 2023 12:00 pm
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Nov 9th, 2023 1:00 pm
Rallybio to Present at Upcoming Investor Conferences in November
- Nov 8th, 2023 1:00 pm
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
- Nov 2nd, 2023 1:15 pm
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
- Oct 3rd, 2023 12:00 pm
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
- Sep 3rd, 2023 4:00 pm
Rallybio to Present at Upcoming Investor Conferences in September
- Aug 31st, 2023 12:00 pm
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
- Aug 8th, 2023 12:00 pm
Scroll